# Biolevate

> Life-sciences automation company that raised a €30 million Series A and opened a Boston office.

## Why it is interesting

Strong life-sciences AI theme, company-reported 20x ARR growth, and a material Series A from recognizable investors.

## Profile

- **Latest funding:** Series A — €30M (September 22, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** series-a
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-09-30
- **Latest funding investors:** RAISE France, Orange Ventures, MSD Global Health Innovation Fund, EQT Ventures

## Key facts

- Sep 22, 2026: €30M Series A
- Company said ARR increased 20x over the prior 12 months

## Funding history

- Series A · €30M · September 22, 2026
  Source: https://www.biolevate.com/news/series-a-2026

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 30, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/biolevate